A Study of Red Blood Cell Alloimmunization and Autoimmunization Among 200 Multitransfused Egyptian β Thalassemia Patients

Overview

Journal Sci Rep

Specialty Science

Date 2020 Dec 4

PMID 33273689

Citations 11

Authors

Amal El-Beshlawy

Alshymaa Ahmed Salama

Mohamed Roshdy El-Masry

Noha M El Husseiny

Asmaa M Abdelhameed

Affiliations

Soon will be listed here.

Abstract

The development of hemolytic erythrocyte alloantibodies and autoantibodies complicates transfusion therapy in thalassemia patients. These antibodies ultimately increase the need for blood and intensify transfusion complications. There is a scanty data on the frequency of RBC alloimmunization and autoimmunization in Egyptian β thalassemia patients as pretransfusion antibody screening is not routinely performed. We studied the frequency of alloimmunization and autoimmunization among 200 multiply transfused β thalassemia patients and investigated the factors that possibly affect antibody formation. Of the 200 patients in our study, 94 were males and 106 females, with the age range of 2-37 years. Alloantibodies were detected in 36 (18%) of the patients, while autoantibodies were detected in 33 (16.5%). The dominant alloantibodies were directed against Kell (33%) and Rh (24.4%) groups. Alloimmunization had a significant relationship with treatment duration and the frequency of transfusion (P = 0.007, 0.001, respectively). The presence of autoantibodies was significantly related to age (P = 0.001), total number of transfused units (P = 0.000) and splenectomy (P = 0.000). The high prevalence of alloimmunization in the study population disclosed the need for providing phenotypically matched cells for selective antigens especially for Kell and Rh subgroups to reduce risk of alloimmunization and increase the efficiency of blood transfusion.

Citing Articles

Erythrocyte Alloimmunization and Autoimmunization in the Pediatric Population: A Multicenter, Cross-Sectional Study in Central China.

Wang Y, Yang Y, Li Z, Li W, Hu H, Zhao D Transfus Med Hemother. 2024; 51(6):402-413.

PMID: 39664460 PMC: 11630902. DOI: 10.1159/000538448.

Assessment of erythrocyte alloimmunization among patients treated at a Brazilian university hospital.

Contelli H, Oliveira M, Ido A, Francalanci E, Terra P, Filho E Hematol Transfus Cell Ther. 2024; 46 Suppl 5:S128-S135.

PMID: 39261147 PMC: 11670643. DOI: 10.1016/j.htct.2024.04.128.

Red blood cell alloimmunization in blood transfusion-dependent β thalassemia major patients in Sana'a City-Yemen.

Almorish M, Al-Absi B, Elkhalifa A, Alhamidi A, Abdelrahman M Sci Rep. 2024; 14(1):1005.

PMID: 38200206 PMC: 10782003. DOI: 10.1038/s41598-024-51561-2.

Study of the Frequency and Specificity of Red Cell Antibodies in Patients with Hemoglobinopathies.

Wilson M, El Masry M, El-Ghamrawy M, El-Hadi N, Abou-Elalla A Indian J Hematol Blood Transfus. 2023; 39(4):579-585.

PMID: 37786822 PMC: 10542054. DOI: 10.1007/s12288-023-01651-4.

Characterization of pediatric transfusion-dependent thalassemia patients in a large academic center.

Zarrabian D, Hanna M J Clin Lab Anal. 2023; 37(17-18):e24962.

PMID: 37665129 PMC: 10623514. DOI: 10.1002/jcla.24962.

References

Belizaire R, Mack J, Kadauke S, Kim Y, Saidman S, Makar R . Red blood cell alloantibodies are associated with increased alloimmunization against human leukocyte antigens. Transfusion. 2019; 59(7):2256-2263. DOI: 10.1111/trf.15306. View

Kountouris P, Lederer C, Fanis P, Feleki X, Old J, Kleanthous M . IthaGenes: an interactive database for haemoglobin variations and epidemiology. PLoS One. 2014; 9(7):e103020. PMC: 4109966. DOI: 10.1371/journal.pone.0103020. View

Chao Y, Wu K, Lu J, Shih M, Peng C, Chang C . Red blood cell alloimmunisation among Chinese patients with β-thalassaemia major in Taiwan. Blood Transfus. 2012; 11(1):71-4. PMC: 3557491. DOI: 10.2450/2012.0153-11. View

Matteocci A, Pierelli L . Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang. 2013; 106(3):197-208. DOI: 10.1111/vox.12086. View

Romphruk A, Simtong P, Butryojantho C, Pimphumee R, Junta N, Srichai S . The prevalence, alloimmunization risk factors, antigenic exposure, and evaluation of antigen-matched red blood cells for thalassemia transfusions: a 10-year experience at a tertiary care hospital. Transfusion. 2018; 59(1):177-184. DOI: 10.1111/trf.15002. View

Saied D, Kaddah A, Badr Eldin R, Mohaseb S . Alloimmunization and erythrocyte autoimmunization in transfusion-dependent Egyptian thalassemic patients. J Pediatr Hematol Oncol. 2011; 33(6):409-14. DOI: 10.1097/MPH.0b013e3182208154. View

Thompson A, Cunningham M, Singer S, Neufeld E, Vichinsky E, Yamashita R . Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. Br J Haematol. 2011; 153(1):121-8. PMC: 5728106. DOI: 10.1111/j.1365-2141.2011.08576.x. View

Pelegrinis E, KARAKLIS A . Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang. 1987; 52(1-2):95-8. DOI: 10.1111/j.1423-0410.1987.tb02999.x. View

Bhatti F, Salamat N, Nadeem A, Shabbir N . Red cell immunization in beta thalassaemia major. J Coll Physicians Surg Pak. 2004; 14(11):657-60. DOI: 11.2004/JCPSP.657660. View

10.

Poole J, Daniels G . Blood group antibodies and their significance in transfusion medicine. Transfus Med Rev. 2006; 21(1):58-71. DOI: 10.1016/j.tmrv.2006.08.003. View

11.

Ahmed A, Hasan N, Ragab S, Habib S, Emara N, Aly A . Red cell alloimmunization and autoantibodies in Egyptian transfusion-dependent thalassaemia patients. Arch Med Sci. 2012; 6(4):592-8. PMC: 3284076. DOI: 10.5114/aoms.2010.14473. View

12.

Floss A, Strauss R, Goeken N, Knox L . Multiple transfusion fail to provoke antibodies against blood cell antigens in human infants. Transfusion. 1986; 26(5):419-22. DOI: 10.1046/j.1537-2995.1986.26587020115.x. View

13.

Ho H, Ha S, Lam C, Chan G, Lee T, Chiang A . Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. Blood. 2001; 97(12):3999-4000. DOI: 10.1182/blood.v97.12.3999. View

14.

Hendrickson J, Tormey C . Red Blood Cell Antibodies in Hematology/Oncology Patients: Interpretation of Immunohematologic Tests and Clinical Significance of Detected Antibodies. Hematol Oncol Clin North Am. 2016; 30(3):635-51. DOI: 10.1016/j.hoc.2016.01.006. View

15.

Davis B, Porter J . Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol. 2003; 509:91-125. DOI: 10.1007/978-1-4615-0593-8_6. View

16.

Gupta R, Singh D, Singh B, Rusia U . Alloimmunization to red cells in thalassemics: emerging problem and future strategies. Transfus Apher Sci. 2011; 45(2):167-70. DOI: 10.1016/j.transci.2011.07.014. View

17.

Chou S, Liem R, Thompson A . Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol. 2012; 159(4):394-404. DOI: 10.1111/bjh.12061. View

18.

Tormey C, Hendrickson J . Transfusion-related red blood cell alloantibodies: induction and consequences. Blood. 2019; 133(17):1821-1830. PMC: 6484385. DOI: 10.1182/blood-2018-08-833962. View

19.

Sigler E, Shvidel L, Yahalom V, Berrebi A, Shtalrid M . Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion-severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab. Transfusion. 2009; 49(7):1370-4. DOI: 10.1111/j.1537-2995.2009.02163.x. View

20.

el-Danasoury A, Eissa D, Abdo R, Elalfy M . Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program. Transfusion. 2011; 52(1):43-7. DOI: 10.1111/j.1537-2995.2011.03234.x. View